Telix Pharmaceuticals (ASX:TLX) receives TGA approval for Ill
Telix Pharmaceuticals (TLX) has received approval from the Australian drug watchdog for…
Telix Pharmaceuticals Limited (ASX:TLX)
$6.60
-0.03 (-0.45%)
MCAP $1.890B
Last trade
16.10pm 30/11/2021
20mins delayed
Latest Announcements
16/11/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
2,966
MCap
02/11/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
21/10/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
21/10/2021TLXTelix Pharmaceuticals Limited
20/10/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
29/09/2021TLXTelix Pharmaceuticals Limited
29/09/2021TLXTelix Pharmaceuticals Limited
29/09/2021TLXTelix Pharmaceuticals Limited
Company Overview
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The Company's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.
